A review of published evidence reporting on the efficacy and pharmacology of lurasidone

Expert Opinion on Pharmacotherapy
Roger S McIntyreJeanette M Jerrell

Abstract

Lurasidone is a benzisothiazol derivative, approved by the US Food and Drug Administration for the acute treatment of adults with schizophrenia. Lurasidone's binding affinities are highest for the 5-HT(2A), 5-HT(7), and D(2) receptors; with lower and similar binding affinities for the norepinephrine α(2C) and 5-HT(2C) receptor subtypes. It has demonstrated efficacy in fixed-dose studies across a variable dose range (i.e., 40 - 160 mg), with a recommended starting dose of 40 mg and a maximum recommended dose of 80 mg. Lurasidone's preclinical profile is predictive not only of efficacy against psychotic and negative symptoms but also of affective symptomatology and cognitive deficits. Controlled trials are currently underway to evaluate lurasidone's efficacy in bipolar depression as well as its procognitive effects in individuals with schizophrenia. Lurasidone is administered once a day with ≥ 350 calories of food, regardless of fat content. Lurasidone is not known to adversely affect body composition, anthropometrics, metabolic and/or electrocardiographic parameters. Although prolactin elevation might be observed, prolactin-related adverse events are rarely reported. This paper presents the pharmacodynamics and pharmacokinetics ...Continue Reading

References

Jul 15, 2015·Chemical Society Reviews·Tegan P Stockdale, Craig M Williams
Jun 3, 2017·BioMed Research International·Michele FornaroAndrea de Bartolomeis

Citations

Jun 6, 2009·The Journal of Clinical Psychiatry·Mitsutaka NakamuraAntony Loebel
Apr 21, 2010·The Journal of Pharmacology and Experimental Therapeutics·Tadashi IshibashiMitsutaka Nakamura
May 12, 2011·The Journal of Pharmacology and Experimental Therapeutics·M HoriguchiHerbert Y Meltzer
Jun 17, 2011·The American Journal of Psychiatry·Herbert Y MeltzerAntony Loebel
Aug 16, 2011·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Kyeong-Ryoon LeeTae-Sung Koo

Related Concepts

Metabolic Process, Cellular
PRL
Phase 3 Clinical Trials
Olanzapine
Schizophrenia
Serotonin
Lurasidone
Bipolar Disorder
Evaluation Studies, FDA Phase II as Topic
Adverse Event

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here